Please login to the form below

Not currently logged in
Email:
Password:

Bristol Myers-Squibb launch Best to Test

Bristol Myers-Squibb is sponsoring a new initiative to improve the level of chronic myeloid leukaemia monitoring
Bristol Myers-Squibb is sponsoring a new initiative to improve the level of chronic myeloid leukaemia (CML) monitoring on the back of results of a recent survey that indicate that doctors are not doing enough in this area.

While UK GPs came out top of the poll of 550 physicians and specialists across Europe, the results show that 47 per cent of the respondents are not carrying out regular monitoring for CML patients.

The Best to Test initiative will push forward a drive to change and improve the level and quality of CML monitoring and testing after the data from the survey suggested that better education and support is needed.

"Resistance and intolerance to treatments are real concerns for patients and their physicians and monitoring in the correct way is key to achieving the longest possible survival rates," said Tony Gavin, chief executive of Leukaemia CARE UK.

23rd June 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Conversis

Conversis is a translation company specialising in translation and localisation for the Life Science and Pharmaceutical industry, with particular focus...

Latest intelligence

Where next in Alzheimer’s disease R&D?
How past failures and emerging biology are reshaping drug development...
Brain scan
Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...

Infographics